Use of abietic acid in the treatment of alzheimer's disease
By repairing the intestinal barrier, reshaping the microbial community structure, promoting the production of short-chain fatty acids, and regulating pyrimidine metabolism in brain tissue, pineic acid has overcome the efficacy bottleneck of existing Alzheimer's disease treatment strategies and achieved safe and efficient intervention for Alzheimer's disease.
Patent Information
- Application Number
- CN202610605053.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-06
- Publication Date
- 2026-08-25
AI Technical Summary
Current Alzheimer's disease treatment strategies have reached a bottleneck in efficacy. Treatment strategies that target single pathological targets in the brain have little effect, and existing probiotic or fecal microbiota transplantation protocols have problems such as low strain colonization efficiency, large individual differences, and high safety risks. There is a lack of systematic research that longitudinally links changes in gut microbiota with brain function.
Using pineal acid (SCA) as the active ingredient, this product aims to improve Alzheimer's disease through a cross-organ gut-brain axis mechanism by repairing the intestinal barrier, reshaping the gut microbiota structure, promoting the production of short-chain fatty acids, and regulating pyrimidine metabolism in brain tissue.
It significantly improves cognitive and memory dysfunction, reduces abnormal Aβ deposition in the brain, reduces oxidative stress damage, regulates gut microbiota, restores metabolic homeostasis in hippocampal tissue, and provides a safe and efficient intervention method for Alzheimer's disease.
Smart Images

Figure CN122624459A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, and in particular to the application of pine acid in the treatment of Alzheimer's disease. Background Technology
[0002] Alzheimer's disease (AD) is an insidious, progressive neurodegenerative disease and the most common cause of dementia in the elderly. Its core clinical manifestations include progressive memory loss, cognitive impairment, executive function decline, and neuropsychiatric abnormalities. The main neuropathological features of AD are: senile plaques formed by the abnormal extracellular aggregation of β-amyloid-β (Aβ), neurofibrillary tangles formed by the intracellular deposition of hyperphosphorylated tau protein, and widespread neuronal loss in the hippocampus and cerebral cortex accompanied by synaptic dysfunction. According to statistics from the World Health Organization and Alzheimer's Disease International, the number of people with AD worldwide has exceeded 55 million, and with the increasing aging of the global population, it is projected to surpass 150 million by 2050, posing an extremely serious public health challenge and socioeconomic burden.
[0003] Despite decades of research into the pathological mechanisms of Alzheimer's disease (AD), current clinical drug intervention strategies remain extremely limited, with significant efficacy bottlenecks and safety deficiencies. First-line clinical drugs primarily consist of cholinesterase inhibitors (such as donepezil and rivastigmine) and N-methyl-D-aspartate receptor antagonists (such as memantine). These drugs only achieve short-term symptom relief or stabilization in some patients, lacking effective delay or reversal of the fundamental pathological processes of the disease—Aβ plaque formation and neuronal death. While monoclonal antibody drugs targeting Aβ, such as aducanamab (which received accelerated approval from the FDA in 2021) and subsequent lencanemab, have shown some biological activity in clearing Aβ deposits in the brain, their clinical cognitive benefits are minimal, and they are accompanied by serious adverse reactions such as amyloid-related imaging abnormalities, cerebral edema, and microbleeds. More critically, current technologies generally overlook the complex interactions between AD as a systemic disease and peripheral organs (especially the gastrointestinal tract), resulting in treatment strategies targeting single brain pathological targets often yielding minimal results.
[0004] In recent years, the rise of the gut-brain axis theory has provided a new research paradigm for elucidating the pathogenesis of Alzheimer's disease (AD). Numerous clinical cohort studies and animal model experiments have confirmed a close causal link between the occurrence and development of AD and gut microbiota imbalance. One drawback of existing technologies is that, although the phenomenon of gut microbiota dysbiosis in AD states (e.g., increased abundance of pro-inflammatory Proteobacteria and significantly reduced abundance of beneficial short-chain fatty acid-producing genera such as Bifidobacterium and Lactobacillus) has been observed, the downstream cross-organ signal transduction mechanisms are still insufficiently understood. AD-associated intestinal barrier dysfunction ("leaky gut") leads to a large influx of lipopolysaccharides (LPS) from Gram-negative bacteria into the bloodstream, activating microglia in the peripheral and even central nervous systems, triggering a neuroinflammatory cascade. However, current probiotic- or fecal microbiota transplantation-based regulatory protocols suffer from technical limitations such as low strain colonization efficiency, significant individual variability, and high safety risks associated with live bacteria preparations, and are difficult to standardize in terms of production and quality control.
[0005] Short-chain fatty acids (SCFAs), as key metabolites of dietary fiber and some unsaturated fatty acids fermented by gut microbiota, are considered important messengers connecting gut microbiota ecology and brain function. Existing research shows that SCFAs (especially butyrate) can cross the blood-brain barrier via monocarboxylic acid transporters, not only acting as histone deacetylase inhibitors to regulate gene transcription in the brain but also directly providing energy substrates for neurons. Current metabolomics studies on Alzheimer's disease (AD) are mostly limited to single biological samples (such as serum or brain tissue analysis alone), lacking systematic studies that longitudinally cascade the process of "gut microbiota alteration—gut barrier repair—dynamic SCFA generation—hippocampal key metabolite remodeling." In particular, the quantitative response relationship between endogenous metabolic reprogramming (including RNA transcriptional dysregulation caused by pyrimidine metabolism disorders and oxidative stress damage exacerbated by taurine metabolism abnormalities) and gut-derived SCFA levels remains unclear in the hippocampus, the earliest and most sensitive functional region affected by AD.
[0006] SCA (cis-5,11,14-eicosatotrienoic acid) is a non-methylene-spaced Δ5-polyunsaturated fatty acid. It is mainly found in the seed oils of certain gymnosperms such as Torreya grandis and Taxus chinensis. Existing literature reports that SCA possesses certain anti-inflammatory activities and improves lipid accumulation. However, there are no reports on the effectiveness of SCA in improving Alzheimer's disease. In summary, given the difficulties in clinical translation and significant side effects of existing anti-AD drugs, a novel treatment strategy is urgently needed in this field. Summary of the Invention
[0007] The purpose of this invention is to provide an application of pine acid in the treatment of Alzheimer's disease, which has important scientific significance and clinical translational value for developing safe and efficient new methods for Alzheimer's disease intervention.
[0008] The technical solution adopted by this invention to solve its technical problem is: Application of pine acid in the preparation of drugs for treating Alzheimer's disease.
[0009] Application of pine acid in the preparation of dietary supplements to improve Alzheimer's disease.
[0010] Application of pine acid in the preparation of functional foods that improve Alzheimer's disease.
[0011] A pharmaceutical composition for the prevention and / or treatment of Alzheimer's disease, comprising a therapeutically effective amount of pine acid and pharmaceutically acceptable excipients.
[0012] The therapeutic effective dose of pine acid is 500-1000 mg / kg / day.
[0013] The dosage form of the pharmaceutical composition is an oral preparation.
[0014] This invention reveals for the first time that pine acid improves Alzheimer's disease through a cross-organ gut-brain axis mechanism of "repairing the intestinal barrier, reshaping the microbiota structure, promoting the production of short-chain fatty acids, and regulating pyrimidine metabolism in brain tissue," providing a basis for its application in pharmaceuticals, dietary supplements, and functional foods.
[0015] The beneficial effects of this invention are: (1) SCA intervention can significantly improve cognitive and memory dysfunction and protect the structural integrity of brain tissue; (2) SCA can reduce abnormal Aβ deposition in the brain, reduce the number and distribution range of Aβ positive plaques, and alleviate the core pathological damage of AD; it can also regulate the balance of oxidative stress in the body, reduce the content of oxidative damage markers MDA and NO in brain and liver tissues, increase the activity of antioxidant enzymes SOD and GSH-Px, and alleviate tissue damage mediated by oxidative stress. (3) SCA can improve pathological damage and cognitive dysfunction of the central nervous system by regulating the gut microbiota; (4) SCA restores metabolic homeostasis in the hippocampus of AD mice at the metabolic level by regulating two core pathways of taurine and taurine metabolism and pyrimidine metabolism and by reverting the levels of key differential metabolites, providing metabolomics evidence for the neuroprotective effect of SCA. Attached Figure Description
[0016] Figure 1The following are graphs showing the effect of SCA on memory impairment in APP / PS1 mice: (A) escape latency (s), (B) escape latency distance (m), (C) representative swimming trajectory of mice in the water maze on day 5, (D) main movement trajectories of mice in each group during the spatial exploration experiment, (E) number of times mice crossed the platform during the exploration experiment, (F) swimming speed (s), (G) time for the first crossing of the platform during the exploration experiment, (H) percentage of time spent in the target quadrant, and (I) percentage of distance spent in the target quadrant. Compared with group C, *p<0.05, **p<0.01; compared with group M, #p<0.05, ##p<0.01.
[0017] Figure 2 The results of the Y-maze experiment are shown in the figure: (A) spontaneous alternation rate, (B) representative movement trajectory. Compared with group C, *p<0.05, **p<0.01; compared with group M, #p<0.05, ##p<0.01.
[0018] Figure 3 The following is a diagram showing the effect of SCA on the pathology of brain tissue in APP / PS1 mice: (A) HE staining of brain tissue, (B) Nissl staining of brain tissue.
[0019] Figure 4 The following diagram illustrates the effects of SCA on oxidative stress levels in the brain and liver tissues of APP / PS1 mice: (A) Effect of SCA on SOD activity in brain tissue, (B) Effect of SCA on GSH-PX activity in brain tissue, (C) Effect of SCA on MDA content in brain tissue, (D) Effect of SCA on NO content in brain tissue, (E) Effect of SCA on SOD activity in liver tissue, (F) Effect of SCA on GSH-PX activity in liver tissue, (G) Effect of SCA on MDA content in liver tissue, and (H) Effect of SCA on NO content in liver tissue. Compared with group C, *p<0.05, **p<0.01; compared with group M, #p<0.05, ##p<0.01.
[0020] Figure 5 This is a diagram showing the effect of CA on Aβ deposition in the brain tissue of APP / PS1 mice.
[0021] Figure 6 The following diagram shows the effects of SCA on colonic inflammation and structure in APP / PS1 mice: (A) HE staining of colonic tissue, (B) Effects of SCA on inflammatory factors TNF-α, IL-1β, and IL-6 in colonic tissue. Compared with group C, *p<0.05, **p<0.01; compared with group M, #p<0.05, ##p<0.01.
[0022] Figure 7 This is a graph showing the effect of SCA on the gut microbiota dysbiosis index.
[0023] Figure 8 It is a diagram showing the effect of SCA on the intestinal flora health index.
[0024] Figure 9 It is a Circos sample-genus relationship diagram showing the effect of SCA on the intestinal flora composition at the genus level in APP / PS1 mice; the left semi-circle represents the genus composition, and the right semi-circle represents the distribution of each genus in the experimental group.
[0025] Figure 10 It is a differential test diagram showing the effect of SCA on the intestinal flora composition at the genus level in APP / PS1 mice.
[0026] Figure 11 It is a diagram showing the effect of SCA on SCFAs in the colon contents of APP / PS1 mice.
[0027] Figure 12 It is a diagram of the results of metabolic pathway enrichment analysis. Specific implementation manners
[0028] The technical solutions of the present invention will be further specifically described below through specific embodiments.
[0029] In the present invention, unless otherwise specified, the raw materials, equipment, etc. used can be purchased from the market or are commonly used in the art. The methods in the following embodiments are conventional methods in the art unless otherwise specified.
[0030] Example 1: Animal experiment design Animal experiment design: SPF-grade C57BL / 6 mice and APP / PS1 double transgenic mice (male, 30 ± 2 g) at 16 weeks of age were purchased from Hangzhou Ziyuan Animal Technology Co., Ltd. (production and use license number: SCXK (Zhe) 2019-0004). Mouse bedding and feed were purchased from Suzhou Shuangshi Experimental Animal Feed Technology Co., Ltd.
[0031] Sixteen-week-old male C57BL / 6J mice and transgenic APP / PS1 mice were placed in the standard barrier environment of the Animal Experiment Center of Zhejiang Academy of Agricultural Sciences. The environmental conditions were maintained at room temperature (25 ± 2 °C), humidity (50 ± 5%), and a 12-hour light-dark cycle, and sterile water and ordinary feed were given. This animal experiment study has been approved by the Ethics Review Committee of Zhejiang Academy of Agricultural Sciences (ethics review number: 25ZALAS43), and the experiment was carried out strictly in accordance with the regulations of the Ethics Committee of Zhejiang University of Technology and the techniques related to the care and use of experimental animals.
[0032] After a one-week acclimatization period, a two-month SCA intervention experiment was initiated. The experiment was divided into five groups (n=10 per group): wild-type control group (C group): C57BL / 6J mice, fed with normal diet and administered sterile water by gavage; model group (M group): APP / PS1 mice, administered sterile water by gavage; positive control group (S group): APP / PS1 mice, administered donepezil hydrochloride 0.005 g / kg / d by gavage; low-dose SCA group (SCAL group): APP / PS1 mice, administered SCA 500 mg / kg / d by gavage; high-dose SCA group (SCAH group): APP / PS1 mice, administered SCA 1000 mg / kg / d by gavage.
[0033] Example 2: Pine acid improves cognitive and memory dysfunction in APP / PS1 mice 2.1 Water Maze Experiment Before the experiment, mice underwent a 24-hour acclimatization period in a designated room. The water maze pool (Wored Biotechnology Co., Ltd.) was divided into four quadrants, each labeled with a different identifier. The target quadrant was designated as the first quadrant experiment, and the platform was fixed 1 cm below the water surface in that quadrant. In the navigation experiment, mice were placed in the water from the starting point in different quadrants, and the time required for a mouse to climb onto the platform and remain there for 5 seconds was recorded. If a mouse failed to reach the platform within 60 seconds, it was guided to stay on the platform for 30 seconds to aid memory. This was repeated four times a day for five days. On the sixth day, the underwater platform was removed for testing. During 60-second intervals, each mouse swam in the pool to explore the location previously occupied by the platform. The exploration trajectory of each mouse during training and testing was recorded using water maze software for subsequent analysis.
[0034] The results are as follows Figure 1 As shown. During the navigation phase: the escape latency and path length of mice in group M were significantly longer than those in group C, while groups SCAL, SCAH, and S all significantly shortened the latency and path length. Figure 1 AB). Swimming trajectories showed that the movement paths of group M were random and disordered, while the trajectories of the SCA intervention group were more selective (AB). Figure 1 C). Spatial exploration phase: Compared with group C, mice in group M showed significantly reduced platform crossings, target quadrant time percentage, and distance percentage (p<0.05), and prolonged first platform crossing time (p<0.05); compared with group M, mice in group SCAH showed significantly increased platform crossings (p<0.05), significantly reduced first platform crossing time (p<0.05), and significantly increased target quadrant time and distance percentage (p<0.05). Figure 1 DI).
[0035] In the orientation navigation experiment, the changes in escape latency in different groups of mice over 1 to 5 days reflected their cognitive ability to gradually learn to find fixed platforms. In each experimental group, the escape latency showed a significant decreasing trend over 1-5 days. Group M performed the worst among all groups, indicating impaired learning and memory function in this group. In contrast, the cognitive performance of the groups ingesting different types of pineapple acid (SCA) approached the levels of groups C and S, suggesting that SCA can effectively improve cognitive dysfunction in AD model mice to some extent, and that low concentrations of SCA are more effective than high concentrations. The escape latency distance over five days in the orientation navigation experiment showed that the escape latency distance decreased to varying degrees in all groups compared to the first day as the number of training days increased. Group M showed the smallest decrease in distance, indicating that SCA and donepezil hydrochloride intake can improve memory impairment in AD mice.
[0036] Analysis of the trajectory distribution maps from the navigational positioning experiment revealed that, after training, mice in group C were able to locate the hidden platform underwater using ordered movement trajectories. Compared to group C mice, mice in group M exhibited more random and disordered movement paths. After 60 days of gavage administration of different doses of pine resin, the path lengths for finding the target platform in the SCAL and SCAH groups were shortened, and the routes showed selectivity, indicating that SCA-induced AD impairments in these mice were improved.
[0037] Analysis of the trajectory distribution maps from the spatial exploration experiment revealed that mice in group C exhibited more search trajectories within the quadrant where the original platform was located and quickly located the target quadrant (quadrant I). Mice in group M, however, primarily limited their activity to the edge of the water maze, displaying a circling behavior pattern. Mice in groups S, SCAL, and SCAH showed active platform-finding behavior, with groups S and SCAL exhibiting more concentrated activity trajectories within the original platform quadrant. These results indicate that learning and memory abilities were impaired in group M, while SCA and donepezil hydrochloride both promoted the recovery of memory and learning abilities in AD mice to varying degrees. This experiment statistically analyzed the number of times mice crossed the platform, swimming speed, time to first platform crossing, percentage of time spent in the target quadrant, and percentage of distance to the target quadrant for each group. Compared to group C, group M showed significantly decreased, prolonged, increased, and increased rates of platform crossing, first platform crossing time, percentage of time spent in the target quadrant, and percentage of distance to the target quadrant (P<0.05), while swimming speed showed no significant difference (P>0.05), indicating impaired learning and memory abilities in group M. Compared with group M mice, mice in group SCAL showed a significant increase in the number of times they crossed the platform (P < 0.05), a decrease in the time taken to cross the platform for the first time (P < 0.05), and no significant differences in swimming speed, target quadrant time percentage, and target quadrant distance percentage (P > 0.05). Mice in group SCAH showed a decrease, a prolongation, an increase, and a widening of the number of times they crossed the platform, the time taken to cross the platform for the first time, the target quadrant time percentage, and the target quadrant distance percentage (P < 0.05), respectively, while swimming speed showed no significant difference (P > 0.05). Mice in group S showed significant differences in the number of times they crossed the platform, the target quadrant time percentage, and the target quadrant distance percentage (P > 0.01), a decrease in the time taken to cross the platform for the first time (P < 0.05), and no significant difference in swimming speed (P > 0.05). These findings indicate that intervention with SCA and donepezil hydrochloride can significantly improve the impaired memory ability in AD mice.
[0038] 2.2 Y-maze Experiment The maze consists of three equal arms, with an angle of 120° between them, labeled A, B, and C. Before the experiment, mice were placed in the room for 30 minutes to acclimatize. Each mouse that had not yet entered the maze was placed in the center for 3 minutes to acclimatize. The partitions leading to the three arms were then opened, allowing the mouse to freely explore the maze for 5 minutes, and the results were recorded. After each mouse test, the experimental area was cleaned with alcohol to eliminate odor interference from the previous mouse. The order and number of times the mice entered each arm were recorded. Alternation refers to the mouse entering all three arms of the maze consecutively. The calculation formula is as follows: Spontaneous alternation rate (%) = Number of consecutive entries into three different arms / (Total number of arms entered - 2) × 100%.
[0039] The results are as follows Figure 2 As shown, the spontaneous alternation rates of mice in groups C, M, S, SCAL, and SCAH were 20.59±2.87%, 10.40±2.04%, 18.20±2.39%, 12.99±2.20%, and 17.00±2.54%, respectively. Compared with group C, the spontaneous alternation rate in group M was significantly lower, confirming that APP / PS1 mice had already experienced impairment in working and spatial memory at this stage.
[0040] After intervention with pineapple acid, the spontaneous alternation rate in both the SCAL and SCAH groups was significantly higher than that in the M group, with the SCAH group showing a more significant improvement. The S group also showed a significant improvement in spontaneous alternation performance. These results indicate that SCA can effectively improve spatial working memory impairment in AD mice, showing a behavioral improvement trend consistent with donepezil.
[0041] 2.3 Effects of SCA on pathological damage in brain tissue of APP / PS1 mice To evaluate the ameliorative effect of SCA on brain tissue damage in AD mice, this study observed the effects of HE staining and Nissl body staining on the hippocampal CA1, CA2, CA3, DG, and cortical regions. Figure 3 HE staining can clearly show the morphology of cell nuclei and cytoplasm, and is used to determine the integrity of tissue structure; Nissl body staining reflects the metabolic activity and structural state of neurons, and is an important indicator for evaluating the degree of neuronal damage.
[0042] HE staining results showed that ( Figure 3 In groups A and C, the cortex and hippocampus of mice remained intact, with tightly packed, regularly morphologically regular neurons and clear nucleoplasmic boundaries, showing no obvious pathological changes. In contrast, group M exhibited typical neurodegenerative damage: disordered neuronal arrangement, significantly reduced density, accompanied by cell body atrophy, nuclear pyknosis and deep staining, and increased intercellular spaces, indicating significant structural damage in both the cortex and hippocampus. After intervention with donepezil and SCA, the neuronal structural damage was improved to varying degrees: the arrangement became more regular, cell morphology recovered, nuclear pyknosis was significantly reduced, and the number of abnormal cells was significantly decreased, with the SCAH group showing the most significant structural recovery.
[0043] Nissl staining results further confirmed the above phenomenon. Figure 3(B) In group C, the Nissl bodies in the cytoplasm of neurons were evenly distributed, deeply stained, and abundant, indicating good metabolic activity. In group M, the number of Nissl bodies was significantly reduced, the staining was lighter, and neuronal vacuolation, disordered arrangement, and nuclear condensation were also observed, indicating decreased protein synthesis capacity and severe neuronal structural damage. In contrast, groups S, SCAL, and SCAH all showed an increase in the number of Nissl bodies, deeper staining, and a more uniform distribution, with significant recovery in neuronal arrangement and morphology, among which group SCAH showed the most significant improvement. Overall, pinealool can significantly alleviate neuronal damage in the hippocampus and cortex of APP / PS1 mice, improve tissue structural integrity and neurometabolic characteristics, and the protective effect is more significant in the high-dose group.
[0044] 2.4 Effects of SCA on oxidative stress levels in brain and liver tissues of APP / PS1 mice Oxidative stress is one of the driving factors in the pathological process of Alzheimer's disease. The deposition of Aβ can induce excessive reactive oxygen species production and lead to neuronal apoptosis. To evaluate the ameliorative effect of SCA on oxidative stress in the brain and liver of AD mice, this study examined the levels of representative antioxidant enzymes (SOD, GSH-Px) and oxidative damage markers (MDA, NO) in cortical tissues.
[0045] Figure 4 The results showed that, compared with group C, the levels of MDA and NO in the cortex and liver of mice in group M were significantly increased (p<0.05), while the activities of GSH-Px and SOD were significantly decreased (p<0.05), indicating that the model mice had typical oxidative stress enhancement and decreased antioxidant capacity. After intervention with donepezil hydrochloride and different doses of pine resin, the oxidative stress status of mice in all groups was significantly improved: the levels of MDA and NO were significantly decreased (p<0.05), while the levels of SOD and GSH-Px recovered to varying degrees, approaching the levels of group C. These results indicate that SCA can effectively alleviate oxidative stress damage in the cortex and liver of APP / PS1 mice, increase the activity of antioxidant enzymes, and thus exert a neuroprotective effect.
[0046] 2.5 Effects of SCA on Aβ deposition in the brain of APP / PS1 mice Aberrant deposition of β-amyloid (Aβ) is one of the most typical pathological features of Alzheimer's disease. Accumulation can activate astrocytes and microglia, disrupt the blood-brain barrier, and ultimately induce neuronal degeneration and apoptosis, which is a crucial factor driving cognitive decline. To evaluate the ameliorative effect of SCA on Aβ pathological burden, this study used immunohistochemistry to detect the expression and distribution of Aβ in the brain tissue of APP / PS1 mice. Figure 5The results showed that only a small amount of Aβ-positive staining was observed in the brain tissue of group C mice, while the number of yellowish-brown positive deposits increased significantly in the brain of group M, exhibiting typical Aβ plaque aggregation, suggesting that APP / PS1 mice had developed a significant Aβ pathological burden at this stage. After intervention with donepezil hydrochloride and SCA, the number of Aβ-positive granules decreased, but the degree of improvement differed. Specifically, Aβ deposition was significantly reduced in the SCAH and donepezil groups, with a marked decrease in Aβ plaque density and distribution range; in contrast, the improvement trend in the SCAL group was relatively limited. Overall, SCA can inhibit abnormal Aβ deposition in the brains of APP / PS1 mice, with the SCAH group showing a more significant effect, indicating its potential in improving typical pathological features of AD.
[0047] In summary, behavioral experimental results showed that SCA intervention significantly improved cognitive and memory dysfunction in APP / PS1 mice: In the Morris water maze test, the escape latency of SCA-intervened mice was significantly shortened, the time spent in the target quadrant and the number of platform crossings were significantly increased, the movement trajectory was more purposeful, and spatial learning and memory abilities were significantly improved; In the Y maze test, the spontaneous alternation rate of APP / PS1 mice was significantly increased, and working memory function was effectively improved, with high-dose SCA showing better improvement in some behavioral indicators. Histopathological studies showed that SCA can protect the structural integrity of brain tissue in APP / PS1 mice: HE staining results showed that SCA intervention could alleviate pathological damage such as disorganization and nuclear pyknosis of neurons in the CA1, CA2, CA3, DG areas of the hippocampus and cortical neurons, increase the number of neurons and improve cell morphology; Nissl staining results showed that SCA could increase the number of Nissl bodies and deepen the staining intensity, promoting the recovery of neuronal structure and function, with high-dose SCA showing better protective effects on brain tissue. Meanwhile, SCA can reduce abnormal Aβ deposition in the brain, decrease the number and distribution range of Aβ-positive plaques, and alleviate the core pathological damage of AD; it can also regulate the oxidative stress balance in APP / PS1 mice, reduce the content of oxidative damage markers MDA and NO in brain and liver tissues, increase the activity of antioxidant enzymes SOD and GSH-Px, and alleviate oxidative stress-mediated tissue damage, providing an experimental basis for the development of SCA into neuroprotective products.
[0048] Example 3: Effects of pine acid on intestinal inflammation and gut microbiota in APP / PS1 mice 3.1 Effects of SCA on colonic inflammation and structure in APP / PS1 mice A growing body of research indicates a close link between Alzheimer's disease and impaired intestinal barrier function. Increased intestinal permeability and dysbiosis induce abnormally high levels of inflammatory factors, further affecting the central nervous system and thus exacerbating the pathological progression of AD. This study evaluated the protective effect of serotonin-dependent inflammatory cytokines (SCA) on colonic structure and inflammation in AD mice using hematoxylin and eosin (HE) staining and inflammatory factor analysis. HE staining results showed ( Figure 6 In group C mice, the colonic mucosa structure was intact, the crypt morphology was regular, and there was no obvious inflammatory cell infiltration. In contrast, the colonic tissue of group M showed significant damage, including disordered crypt arrangement, mucosal epithelial cell shedding, submucosal edema, and obvious inflammatory cell infiltration, indicating that the intestinal barrier function was impaired. After intervention with donepezil and SCA, the colonic structure of all treatment groups was significantly improved: the crypt structure was relatively restored, the inflammatory cell infiltration was reduced, and the mucosal edema was alleviated. The morphological improvement was most significant in the donepezil group and the SCAH group.
[0049] To further verify its anti-inflammatory effect, this study detected TNF-α, IL-6, and IL-1β in colon tissue. Figure 6 The results showed that, compared with group C, all three inflammatory factors in group M were significantly elevated (P<0.01), reflecting a significant intestinal inflammatory response in AD mice. Compared with the model group, donepezil and both doses of SCA significantly reduced the levels of TNF-α, IL-6, and IL-1β (P<0.01), with the SCAH group showing the greatest reduction. In conclusion, SCA can alleviate intestinal inflammatory response in APP / PS1 mice by improving intestinal tissue structure and significantly reducing inflammatory factor levels, suggesting that SCA may alleviate AD-related pathological changes by maintaining intestinal barrier integrity and improving intestinal inflammation.
[0050] 3.2 Effects of SCA on the gut microbiota characterization index of APP / PS1 mice The gut microbiota dysbiosis index (MDI) is an important indicator for assessing the degree of imbalance in the gut microbiota ecosystem; a higher value indicates a more severe dysbiosis. For example... Figure 7 As shown, compared with group C, group M had a significantly higher MDI (p<0.05), indicating significant gut microbiota dysbiosis in APP / PS1 mice; however, after intervention, the MDI of groups S, SCAL, and SCAH all decreased to levels not significantly different from group C, indicating that SCA intervention effectively alleviated the microbiota imbalance. Further analysis of the gut microbiota health index (GMHI) revealed ( Figure 8Compared with the M group, the GMHI value of the SCAH group was significantly increased (p<0.01), indicating that high-dose SCA can promote the restoration of the gut microbiota structure to a healthy state. In conclusion, APP / PS1 mice exhibit significant gut microbiota dysbiosis, and SCA intervention, especially SCAH, can significantly reverse the dysbiosis and improve the level of gut microbiota health, thereby exerting a potential neuroprotective effect at the gut-brain axis level.
[0051] 3.3 Effects of SCA on the composition of gut microbiota at the genus level in APP / PS1 mice To further investigate the regulatory role of SCA on the gut microbiota, bacteria with an abundance percentage >0.01 at the genus level were statistically analyzed. (Circos diagram) Figure 9 This visually illustrates the association and distribution of dominant bacterial genera among each sample group, clearly demonstrating the differences in bacterial community structure between different treatment groups. Unclassified *Muribakula* genus ( norank_f__Muribaculaceae ), Alobacherella ( Allobaculum Lactobacillus ( ) Lactobacillus ), Unclassified anaerobic spirochetes (family Phytospiraceae, genus) unclassified_f__Lachnospiraceae ), NK4A136 group of anaerobic spirochetes ( Lachnospiraceae_ NK4A136_group ) and unclassified Ruminococci ( ) unclassified_f__Ruminococcaceae These were the dominant bacterial genera in the six experimental groups. Compared to normal mice, the bacterial genera with significantly increased levels were: Muribaculaceae , Lachnospiraceae_unclassified , Ruminococcaceae_unclassified , Ileibacterium , Prevotellaceae (Multiple genera) Bacteroides , Helicobacter , Bifidobacterium Etc.; Significantly reduced bacterial genera: Allobaculum , Lactobacillus , Ligilactobacillus , Lachnospiraceae_NK4A136_group , Adlercreutzia , Dubosiella , Desulfovibrio Etc. SCA and donepezil intervention showed a significant reversal effect, including an increase in the abundance of beneficial bacteria: Lactobacillus , Ligilactobacillus , Bacilli_unclassified , Sutterellaceae_unclassified Increase, etc. Decrease in inflammation / pathogenic bacteria, such as... Muribaculaceae , Ruminococcaceae_unclassified , Ileibacterium , Helicobacter , Bacteroides , Candidatus Saccharimonas , ParabacteroidesThe number of bacteria decreased. Cluster analysis showed that the SCAL group and the C group were most similar at the genus level, indicating that the low-dose pine acid had a more complete restorative effect on the bacterial community structure. The Kruskal-Wallis H test screened out key genera with significant differences among the groups, including... Allobaculum , Lactobacillus , Ileibacterium , Helicobacter , norank_o_RF39 (P<0.05), these bacterial genera may be the core targets for SCA to exert its intestinal regulatory effects. Figure 10 The above results indicate that SCA intervention can regulate... Lactobacillus , Allobaculum The abundance of key bacterial genera was measured, and the disordered gut microbiota structure of APP / PS1 model mice was remodeled, providing evidence that SCA exerts a neuroprotective effect through the gut-brain axis.
[0052] 3.4 Effects of SCA on SCFAs in the colonic contents of APP / PS1 mice Short-chain fatty acids (SCFAs) are a class of key metabolites produced by the fermentation of dietary fiber by the gut microbiota, primarily including acetic acid, propionic acid, and butyric acid. SCFAs can cross the blood-brain barrier and regulate central nervous system function by activating G protein-coupled receptors in the brain or inhibiting histone deacetylases. Studies have shown that SCFAs play an important role in the gut-brain axis, participating in various physiological processes, and their metabolism is closely related to the pathogenesis and treatment mechanisms of Alzheimer's disease. Therefore, this study measured the levels of SCFAs in the feces of AD mice. Figure 11 As shown, compared with group C, the concentrations of acetic acid, propionic acid, isovaleric acid, butyric acid, hexanoic acid, and valerate were significantly decreased in group M (p<0.01). After intervention with donepezil hydrochloride and different concentrations of SCA, the concentrations of isovaleric acid and butyric acid in all groups of mice were significantly improved (p<0.05), and there was no significant difference in the concentration of valerate among the groups, but there were certain differences in the concentrations of acetic acid, propionic acid, and hexanoic acid among the groups. Specifically, donepezil hydrochloride significantly increased the concentrations of propionic acid and hexanoic acid in colonic contents (p<0.05), SCAL significantly increased the concentration of acetic acid in colonic contents (p<0.01), and SCAH significantly increased the concentrations of acetic acid and propionic acid in colonic contents (p<0.01). These results indicate that each treatment group increased the content of SCFAs to varying degrees, improved the intestinal environment, and thus exerted a neuroprotective effect.
[0053] This study confirms that SCA can improve intestinal microecological dysbiosis in APP / PS1 mice through the effect of "repairing the intestinal barrier, reshaping the microbiota structure, and promoting the generation of SCFAs", and ultimately exert its neuroprotective effect on Alzheimer's disease.
[0054] Example 4: Effects of pine acid on the metabolome of hippocampal tissue 4.1 Preparation of brain tissue metabolomics samples Take approximately 20 mg of hippocampal tissue stored at -80℃ and thaw it on ice. Add a steel ball and homogenize using a ball mill at 30 Hz for 20 seconds. Centrifuge at 3000 rpm for 30 seconds at 4℃ to allow the tissue to settle. Add 400 μL of an aqueous solution containing 70% methanol as an internal standard extraction solution, shake at 1500 rpm for 5 minutes, incubate on ice for 15 minutes, centrifuge at 12000 rpm for 10 minutes at 4℃, transfer 300 μL of the supernatant to a new centrifuge tube, and incubate at -20℃ for 30 minutes. Centrifuge at 12000 rpm for 3 minutes at 4℃, and transfer 200 μL of the supernatant to the inner liner of a sample vial for LC-MS analysis.
[0055] 4.2 Chromatographic and Mass Spectrometry Detection Conditions Ultra-high performance liquid chromatography (UHPLC) conditions: Waters ACQUITY Premier HSS T3 column (1.8 μm, 2.1 mm × 100 mm); mobile phase A: 0.1% formic acid / water, mobile phase B: 0.1% formic acid / acetonitrile; gradient elution program: 0-2 min, 95%-80% A; 2-5 min, 80%-40% A; 5-6 min, 40%-1% A; 6-7.5 min, 1% A; 7.5-7.6 min, 1%-95% A; 7.6-10 min, 95% A; flow rate: 0.3 mL / min; column temperature: 40 °C; injection volume: 4 μL.
[0056] Mass spectrometry conditions: Thermo Q Exactive HF-X mass spectrometer, electrospray ionization (ESI) source, positive and negative ion mode scanning, mass scan range 75-1000 m / z.
[0057] 4.3 Metabolic Data Processing and Differential Metabolite Screening Raw data were converted to mzML format using ProteoWizard, and peak extraction, alignment, and retention time correction were performed using XCMS. Chromatographic peaks with a missing rate exceeding 50% in each sample group were removed. Missing values were processed using a combination of KNN interpolation and the minimum of 1 / 5, and peak areas were corrected using the SVR method. Metabolite identification was performed by comparison with a self-built database and public databases. Metabolites with a coefficient of variation <0.3 in QC samples were screened. Differential variables were screened using principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and orthogonal partial least squares discriminant analysis (OPLS-DA) combined with S-plots (VIP>1) and t-tests (p<0.05).
[0058] 4.4 Results of Differential Metabolite Identification A total of 52 differentially expressed metabolites were identified in groups C and M. Compared with group C, the levels of 27 metabolites in group M were significantly decreased (including hypoxanthine, L-homoserine, thymidine-5'-phosphate, sebacic acid, 5-aminolevulinic acid, MG (18:1 / 0:0 / 0:0), 2-arachidonic glycerol, cholic acid, inosinic acid, LPE (0:0 / 20:3), etc.), while the levels of 25 metabolites were significantly increased (including S-adenosylmethionine, taurine, L-serine, homovanillic acid, palmitoylethanolamide, docosahexaenoic acid, adrenaline, etc.).
[0059] 4.5 The retrograde effect of pine acid on differential metabolites Compared to group M, the low-dose group of ginsenoic acid showed a reduction in 9 metabolites: carnitine C18:1, carnitine C18:1-OH, taurine, cholic acid, docosahexaenoic acid (DHA), dehydrolithocholic acid, acetylsalicylic acid, 5,8,11-eicosatrienoic acid, and erythritol. The high-dose group of ginsenoic acid showed a reduction in 9 metabolites: thymidine-5'-phosphate (dTMP), sebacic acid, 5-aminolevulinic acid, MG (18:1 / 0:0 / 0:0), 3-methylsalicylic acid, DHA, dehydrolithocholic acid, acetylsalicylic acid, and furfural diethyl acetal.
[0060] 5.6 Metabolic pathway enrichment analysis Fifty-two differentially expressed metabolites were submitted to the Metaboanalyst 4.0 platform for pathway enrichment analysis. Using an impact value > 0.05 as the screening criterion, nine key metabolic pathways were identified. Figure 12 A): Folic acid-mediated one-carbon unit metabolism, cysteine and methionine metabolism, glycine / serine / threonine metabolism, taurine and linolenic acid metabolism, purine metabolism, pentose and glucuronic acid interconversion, glycerophospholipid metabolism, pyrimidine metabolism, and amino sugar and nucleotide sugar metabolism. Among these, psoralen can significantly regulate two pathways: taurine and linolenic acid metabolism and pyrimidine metabolism. Figure 12 B, p<0.05).
[0061] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the present invention in any way. Other variations and modifications are possible without departing from the technical solutions described in the claims.
Claims
1. Application of pine acid in the preparation of drugs for treating Alzheimer's disease.
2. Application of pine acid in the preparation of dietary supplements to improve Alzheimer's disease.
3. Application of pine acid in the preparation of functional foods that improve Alzheimer's disease.
4. A pharmaceutical composition for the prevention and / or treatment of Alzheimer's disease, characterized in that, It contains a therapeutically effective amount of pine acid and pharmaceutically acceptable excipients.
5. The pharmaceutical composition according to claim 4, characterized in that, The therapeutic effective dose of pine acid is 500-1000 mg / kg / day.
6. The pharmaceutical composition according to claim 4, characterized in that, The dosage form of the pharmaceutical composition is an oral preparation.
